Bill Gross warns on gold momentum as regional bank stocks tumble
TURKU, Finland - Faron Pharmaceuticals Ltd. (AIM:FARN, First North: FARON), a clinical-stage biopharmaceutical company, has registered 527,948 new ordinary shares in the Finnish Trade Register, according to a company announcement Friday.
The registration follows the company’s approval of the exercise of 527,948 special rights for an aggregate subscription price of €986,998.79.
The newly issued shares will rank equally with existing shares in all respects. Following the issuance, Faron’s total number of ordinary shares has increased to 117,593,545.
The company continues to hold 4,142,678 shares in treasury, resulting in a total of 113,450,867 voting rights. This figure may be used by shareholders to determine notification requirements regarding changes to their interests in the company.
Trading of the new shares is expected to commence on First North and AIM on or around October 6, 2025, based on the press release statement.
Faron Pharmaceuticals focuses on developing novel immunotherapies for various conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.